Terms: = Leukemia AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679
363 results:
1. Discovery of LLC0424 as a Potent and Selective
Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
[TBL] [Abstract] [Full Text] [Related]
2. Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.
Thomas ME; Qi W; Walsh MP; Ma J; Westover T; Abdelhamed S; Ezzell LJ; Rolle C; Xiong E; Rosikiewicz W; Xu B; Loughran AJ; Pruett-Miller SM; Janke LJ; Klco JM
Leukemia; 2024 May; 38(5):991-1002. PubMed ID: 38454121
[TBL] [Abstract] [Full Text] [Related]
3. Childhood-onset systemic lupus erythematosus (cSLE) and malignancy: a nationwide multicentre series review.
Brufatto MZ; Lanças SHS; de Albuquerque Pedrosa Fernandes T; Sallum AME; Campos LMA; Sakamoto AP; Terreri MT; Sztajnbok FR; Bica BERG; Ferriani VPL; de Carvalho LM; Silva CAA; Saad-Magalhaes C
Adv Rheumatol; 2024 Feb; 64(1):13. PubMed ID: 38321580
[TBL] [Abstract] [Full Text] [Related]
4. Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Sechaud R; Gu H; Rahmanzadeh G; Taylor A; Chiparus O; Sharma GK; Breitschaft A; Menssen HD
Cancer Chemother Pharmacol; 2024 May; 93(5):439-453. PubMed ID: 38270613
[TBL] [Abstract] [Full Text] [Related]
5. Micafungin twice-a-week for prophylaxis of invasive Aspergillus infections in children with acute lymphoblastic leukaemia: A controlled cohort study.
Bury D; Wolfs TFW; Muilwijk EW; Fiocco M; Pieters R; Brüggemann RJ; Tissing WJE
Int J Antimicrob Agents; 2024 Jan; 63(1):107058. PubMed ID: 38081549
[TBL] [Abstract] [Full Text] [Related]
6. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
Brivio E; Pennesi E; Willemse ME; Huitema ADR; Jiang Y; van Tinteren HDR; van der Velden VHJ; Beverloo BH; den Boer ML; Rammeloo LAJ; Hudson C; Heerema N; Kowalski K; Zhao H; Kuttschreuter L; Bautista Sirvent FJ; Bukowinski A; Rizzari C; Pollard J; Murillo-Sanjuán L; Kutny M; Zarnegar-Lumley S; Redell M; Cooper S; Bertrand Y; Petit A; Krystal J; Metzler M; Lancaster D; Bourquin JP; Motwani J; van der Sluis IM; Locatelli F; Roth ME; Hijiya N; Zwaan CM
J Clin Oncol; 2024 Mar; 42(7):821-831. PubMed ID: 38033284
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia.
Liu W; Bai Y; Zhou L; Jin J; Zhang M; Wang Y; Lin R; Huang W; Ren X; Ma N; Zhou F; Wang Z; Ding K
Eur J Med Chem; 2024 Jan; 264():115974. PubMed ID: 38007910
[TBL] [Abstract] [Full Text] [Related]
8. Quality by design approach-based fabrication and evaluation of self-nanoemulsifying drug delivery system for improved delivery of venetoclax.
Rajana N; Chary PS; Pooja YS; Bhavana V; Singh H; Guru SK; Singh SB; Mehra NK
Drug Deliv Transl Res; 2024 May; 14(5):1277-1300. PubMed ID: 37953430
[TBL] [Abstract] [Full Text] [Related]
9. MLPA in the initial genetic screening of patients with acute myeloid leukemia.
Yahya D; Hachmeriyan M; Ruseva T; Chervenkov T; Micheva I
Rom J Intern Med; 2024 Mar; 62(1):44-51. PubMed ID: 37948316
[TBL] [Abstract] [Full Text] [Related]
10. Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancies: A Pharmacokinetic Study.
AbdelMagid AM; Abbassi MM; Ebeid FS; Farid SF; El-Sayed MH
Clin Ther; 2024 Jan; 46(1):e12-e22. PubMed ID: 37925363
[TBL] [Abstract] [Full Text] [Related]
11. Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans.
Hofmann J; Bartůněk A; Hauser T; Sedmak G; Beránek J; Ryšánek P; Šíma M; Slanař O
Leukemia; 2023 Dec; 37(12):2486-2492. PubMed ID: 37789147
[TBL] [Abstract] [Full Text] [Related]
12. Human neurotropic polyomavirus, JC virus, late coding region encodes a novel nuclear protein, ORF4, which targets the promyelocytic leukemia nuclear bodies (PML-NBs) and modulates their reorganization.
Saribas AS; Bellizzi A; Wollebo HS; Beer T; Tang HY; Safak M
Virology; 2023 Oct; 587():109866. PubMed ID: 37741199
[TBL] [Abstract] [Full Text] [Related]
13. A hidden burden of disease in a specific group: Evaluation of COVID-19 seroconversion rates in pediatric patients with leukemia.
Yılmaz Çelebi M; Şahinkaya Ş; Cem E; Akaslan Kara A; Özdağ E; Ayhan FY; Karakaya N; Odaman Al I; Gözmen S; Hilkay Karapınar T; Oymak Y; Bayram SN; Devrim İ
Am J Infect Control; 2024 Mar; 52(3):320-323. PubMed ID: 37726054
[TBL] [Abstract] [Full Text] [Related]
14. Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
Tarlock K; Liu X; Minard CG; Isikwei EA; Reid JM; Horton TM; Fox E; Weigel BJ; Cooper T
Pediatr Blood Cancer; 2023 Dec; 70(12):e30672. PubMed ID: 37710306
[TBL] [Abstract] [Full Text] [Related]
15. Modes of Action of a Novel c-MYC Inhibiting 1,2,4-Oxadiazole Derivative in leukemia and Breast Cancer Cells.
Zhou M; Boulos JC; Omer EA; Klauck SM; Efferth T
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570631
[TBL] [Abstract] [Full Text] [Related]
16. Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions.
Larfors G; Andersson P; Jesson G; Liljebris C; Brisander M; Lennernäs H; Stenke L
Eur J Haematol; 2023 Oct; 111(4):644-654. PubMed ID: 37503797
[TBL] [Abstract] [Full Text] [Related]
17. Substrate oxidation during exercise in childhood acute lymphoblastic leukemia survivors.
Bertrand É; Caru M; Morel S; Bergeron Parenteau A; Belanger V; Laverdière C; Krajinovic M; Sinnett D; Levy E; Marcil V; Curnier D
Pediatr Hematol Oncol; 2023; 40(8):701-718. PubMed ID: 37440691
[TBL] [Abstract] [Full Text] [Related]
18. Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid leukemia.
Gaudy A; Laille E; Bailey R; Zhou S; Skikne B; Beach CL
Clin Pharmacol Ther; 2023 Oct; 114(4):845-852. PubMed ID: 37422689
[TBL] [Abstract] [Full Text] [Related]
19. Sulfhydryl compound levels are associated with ATO-induced side effects in acute promyelocytic leukemia patients.
Sui M; Wei H; Shen X; Gao K; Zhang Z; Zhang Q
Hematology; 2023 Dec; 28(1):2231738. PubMed ID: 37417768
[TBL] [Abstract] [Full Text] [Related]
20. Application of physiologically based pharmacokinetic modeling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukemia.
Adattini JA; Adiwidjaja J; Gross AS; McLachlan AJ
Pharmacol Res Perspect; 2023 Aug; 11(4):e01082. PubMed ID: 37417254
[TBL] [Abstract] [Full Text] [Related]
[Next]
